Trial Search Results

A Phase 1 Study of Engineered Donor Grafts (OrcaGraft/Orca-Q) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft") in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Orca Biosystems, Inc.

Stanford Investigator(s):


  • Biological: OrcaGraft (Orca-Q)


Key Inclusion Criteria:

   1. Age ≥ 18 and ≤ 65 years at the time of enrollment

   2. Diagnosed acute myeloid, lymphoid or mixed phenotype leukemia in complete remission
   (CR) or CR with incomplete hematologic recovery (CRi) or

   3. High or very high risk myelodysplasic syndrome (MDS) including both of the following:

   4. Planned to undergo myeloablative allogeneic hematopoietic stem cell transplant (HCT)

   5. Matched to a related or unrelated donor or to a haploidentical donor

   6. Estimated glomerular filtration rate (eGFR) > 50 mL/minute

   7. Cardiac ejection fraction at rest ≥ 45% or shortening fraction of ≥ 27% by
   echocardiogram or radionuclide scan (MUGA)

   8. Diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) ≥

   9. Total bilirubin < 1.5 times upper limit of normal (ULN) (< 3 times if attributed to
   Gilbert's syndrome) and ALT/AST < 3 times ULN

Key Exclusion Criteria:

   1. Prior allogeneic HCT

   2. Currently receiving corticosteroids or other immunosuppressive therapy. Topical
   corticosteroids or oral systemic corticosteroid doses less than or equal to 10 mg/day
   are allowed.

   3. Planned donor lymphocyte infusion (DLI)

   4. Positive anti-donor HLA antibodies against a mismatched allele in the selected donor

   5. Karnofsky performance score < 70% (Appendix 12.7)

   6. Hematopoietic cell transplantation-specific Comorbidity Index (HCT-CI) > 4 (Appendix

   7. Uncontrolled bacterial, viral or fungal infections (currently taking antimicrobial
   therapy and with progression or no clinical improvement) at time of enrollment

   8. Seropositive for HIV-1 or -2, HTLV-1 or -2

   9. Any uncontrolled autoimmune disease requiring active immunosuppressive treatment

10. Concurrent malignancies or active disease within 1 year, except non-melanoma skin
   cancers that have been curatively resected

11. History of idiopathic or secondary myelofibrosis

12. Women who are pregnant or breastfeeding

Ages Eligible for Study

18 Years - 65 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Kelly Chyan